@IndexInvestor - "I guess ACW doesn't really want this kind of publicity pre-results"
Dr Bill Ketelbey and Actinogen Medical have been retweeted the Sunrise story on Twitter as well as on the Facebook since this morning.
Tweeter 1 - Dr Bill Ketelbey RetweetedSunriseVerified account @sunriseon79 hours ago
Researchers could be on the brink of a revolutionary treatment that reverses the effects of Alzheimer's disease!
Tweeter 2 : Actinogen Medical @ActinogenMed4 hours agoActinogen Medical Retweeted Sunrise
#Xanamem works by targeting & lowering cortisol, the hormone the body processes under stress. In 2016,@ActinogenMed initiated XanADu, a Ph II Safety, Tolerability & Efficacy trial of Xanamem in patients with mild#Alzheimers. Results are expected in less than 3 months from now.
Tweeter 3 - WE Buchan IR @BuchanIR2 hours agoWonderful to see our client
@ActinogenMed's Phase II XanADu trial featured on@7NewsSydney highlighting their important work in helping patients with Alzheimer's
Facebook -#Xanamem works by targeting and lowering #cortisol, the hormone the body processes under #stress. In 2016, Actinogen Medical initiated XanADu, a Ph II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 10mg daily Xanamem in patients with mild Alzheimer’s disease. Patient recruitment and treatment commenced in mid-2017 and was completed in 2018 with 186 patients randomised across 25 sites in Australia, UK and USA. Results are expected in less than 3 months from now.
#clinicaltrials#Actinogen#stressawarenessmonth#Alzheimersdisease
@IndexInvestor - "I guess ACW doesn't really want this kind of...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
